MHCII-peptide tetramer |
Sensitive, epitope-specific, cells are viabl |
Availability of recombinant MHCII molecule, knowledge of epitopes |
Ex vivo: 5 h in vitro: 5–14 days |
ICS, CFSE, CCA, CD154 |
Intracellular cytokine staining (ICS) |
Allows functional detection of whole antigen-specific CD4+ T cell response. |
Cells are non-viable, dependent on specific T-cell function |
4–12 h |
CFSE, CD154, MHCII tetramer |
Cytokine capture assay (CCA) |
Allows functional detection of whole antigen-specific CD4+ T cell response, cells are viable. |
Limited to a few cytokines, carry-over of irrelevant cells |
4–12 h |
MHCII tetramer, CD154, CFSE |
CD154 assay |
Allows detection of whole antigen-specific CD4+ T cell response. |
Dependent on specific T-cell activation |
3–8 h |
ICS, CFSE, CCA, MHCII tetramer |
Elispot |
Sensitive, provides both qualitative and quantitative information. |
Limited to a few cytokines, dependent on specific T-cell function |
Ex vivo: 2–3 days in vitro: 5–14 days |
|
CFSE-dilution assay |
Allows detection of whole antigen-specific CD4+ T cell response |
Limited to dividing cells, by-stander activation |
3–10 days |
ICS, CCA, MHCII tetramer, CD154 |